Body composition predicts poor outcomes and reveals immunometabolic dysfunction via single‐cell profiling in anti‐BCMA CAR T‐treated myeloma

Abstract Chimeric antigen receptor (CAR) T‐cell therapy has transformed the treatment of relapsed or refractory multiple myeloma (RRMM), yet outcomes remain heterogenous. The prognostic role of body composition in this context is unknown. We retrospectively analyzed 108 RRMM patients treated with an...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Thomas C. Wiemers, Michael Rade, Nora Grieb, Maximilian Ferle, Tihomir Dermendzhiev, David Fandrei, Patrick Born, Luise Fischer, Sabine Seiffert, Anja Grahnert, Maik Friedrich, Ronny Baber, Markus Kreuz, Klaus H. Metzeler, Marco Herling, Carmen D. Herling, Madlen Jentzsch, Georg‐Nikolaus Franke, Andreas Boldt, Thomas Neumuth, Urvi A. Shah, Ulrike Köhl, Kristin Reiche, Timm Denecke, Uwe Platzbecker, Vladan Vučinić, Hans‐Jonas Meyer, Maximilian Merz
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Wiley 2026-03-01
coleção:	HemaSphere
Acesso em linha:	https://doi.org/10.1002/hem3.70314
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!